← brief for 2026-09-27 · Slowing decline

SGLT2 Inhibitors Beyond Glycemic Control: Emerging Pharmacological and Cardiovascular Applications A Narrative Review

Paper No results yet Not peer reviewed

Key takeaways

This review explains how SGLT2 inhibitors work. These drugs were made to lower blood sugar, but they also protect the heart and kidneys. The text says they can slow kidney disease and reduce heart failure events. This is a summary of past trials, not a new study.

Who did this work

Sani Anil S.*1, Grace N. Raju2, Shaiju S. Dharan3

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-26
https://doi.org/10.5281/zenodo.22978843